FDA expands Glaxo-Ligand Promacta to hepatitis C patients

Tue Nov 20, 2012 2:22am IST

A GlaxoSmithKline logo is seen outside one of its buildings in west London, February 6, 2008. REUTERS/Toby Melville

A GlaxoSmithKline logo is seen outside one of its buildings in west London, February 6, 2008.

Credit: Reuters/Toby Melville

Related Topics

Stocks

   

(Reuters) - GlaxoSmithKline Plc said U.S. health regulators had approved its drug Promacta for the additional use of treating low platelet count in hepatitis C patients that will allow them to undergo a standard therapy for the liver disease.

The drug, already approved as a treatment for idiopathic thrombocytopenic purpura — low platelet count of unknown cause — was developed along with Ligand Pharmaceuticals Inc.

Ligand shares rose as much as 17 percent in heavy volumes by mid-day on the Nasdaq.

"We believe that Promacta sales are set to see an uptick with approval in a significant population with unmet medical need," Roth Capital analyst Joseph Pantginis said in a note.

About 3.2 million people in the United States have chronic hepatitis C, the most common blood-borne virus, according to the U.S. Centers for Disease Control and Prevention.

Pantginis estimated Promacta sales of $328 million in 2013, corresponding to $24.6 million in revenue for Ligand.

"We maintain our belief that Glaxo is committed to growing the Promacta franchise with approval in additional indications with about 20 clinical trials ongoing," the analyst added.

The drug, also known as eltrombopag, is approved in 90 countries and is marketed under the brand name Promacta in the United States and as Revolade elsewhere.

It is now the first supportive care treatment available to patients who are ineligible or poor candidates for interferon-based hepatitis C therapy due to low platelet counts.

The U.S. Food and Drug Administration's approval was based on results from two late-stage studies that collectively enrolled 1,521 patients.

(Reporting by Prateek Kumar in Bangalore; Editing by Saumyadeb Chakrabarty)

FILED UNDER:

Reuters Showcase

Rajya Sabha Adjourned

Rajya Sabha Adjourned

Parliament disrupted over Mother Teresa remarks.  Full Article 

India's Growth Story

India's Growth Story

S&P raises India's GDP forecasts, says it's a bright spot in Asia.  Full Article 

Yew in ICU

Yew in ICU

Singapore's Lee Kuan Yew still in intensive care - statement.  Full Article 

Fresh Concerns

Fresh Concerns

Wockhardt says FDA raises new concerns about Waluj plant.  Full Article 

Net Rules

Net Rules

Tougher Internet rules to hit cable, telecoms companies.  Full Article 

World Cup 2015

World Cup 2015

Full coverage of cricket world cup in Australia and New Zealand.  Full Coverage 

Music Awards

Music Awards

Ed Sheeran wins best British record at top UK music awards.  Full Article 

Budget Watch

Budget Watch

A look at India’s last five annual budgets.  Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device.  Full Coverage